Skip to Page Content
*Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.


The incretin hormone GLP-1 acts as a satiety hormone, making it a potentially attractive target for the treatment of obesity. This lecture will discuss mechanisms by which GLP-1 affects satiety, review the efficacy of GLP-1-based therapies as weight loss agents in patients with type 2 diabetes, and include preliminary clinical trial data in patients without diabetes mellitus. The safety and current concerns surrounding this type of therapy will also be reviewed.

Disclosures (at time of recording):

  • Barbara McGowan, MD, FRCP, PhD: Novo Nordisk: Principal Investigator – SCALE Study and Administrative Board Member


  • William McCarthy, MD, FOMA: Ridgetop Research: Offered Expert Opinion on Qsymia
  • Craig Primack, MD, FACP, FOMA: Nestle: Speaker, Focus Group Member; VIVUS: Speaker, Consultant; Diet Owl Smart Phone Application: Founder
  • Eric Westman, MD, MHS, MFOMA: VIVUS, Inc.: National Advisory Board and Speaker’s Bureau; KE Diet: Scientific Advisory Board Member
  • Nothing to Disclose: Sandra Christensen, MSN, ARNP, FOMA; Krishna Doniparthi, MD, FOMA; U. Inge Ferguson, DO, FACOI, FOMA; Brent Gear, DO; Charles Halliman; Deborah Bade Horn, DO, MPH, MS, MFOMA; Carl Knopke, MD, FOMA; Dana Mansell; Jeremy McConnell, MD, FOMA; Timothy McCormick, DO, MPH; Daisy Merey, MD, PhD; Scott Rigden, MD, FAAFP, MFOMA; Stacy Schmidt, PhD; Jennifer Seger, MD, FOMA; Harold Seim, MD, MPH, FOMA; Laurie Traetow, CAE


Presentation Information
Presentation Date:
March 29, 2017
Expiration Date:
December 31, 2020 11:55 PM
Presentation Objectives
  • Evaluate the potential for glucagon like peptide-1 to serve as a medical treatment for obesity.
GLP-1-based Therapies, a Viable Medical Treatment for Obesity?
Dr. Barbara McGowan is a consultant of diabetes and endocrinology at Guy's and St Thomas' Hospital in London. She earned her Ph.D. from the Imperial College London in 2007 after investigating the role of gut hormones and other neuropeptides in appetite control. She currently leads the obesity bariatric service at Guy's and St Thomas' Hospital, where she manages patients with complex obesity. Her areas of interest include gut hormones, obesity, and remission of type 2 diabetes following bariatric surgery.  
Individual topic purchase: Selected
Share This
Preview GLP-1-based Therapies, a Viable Medical Treatment for Obesity?Preview GLP-1-based Therapies, a Viable Medical Treatment for Obesity?
All Access Subscription
Use for All Access  account holders only
To continue, you need to log in to oma. If you have any questions about your account please contact us at 1-866-702-3278.
Email Address:
OMA Member Price: